Pharmacologic effects of paclitaxel in human bladder tumors

Cancer Chemotherapy and Pharmacology

Volumn 41, Issue 1, 1997, Pages 69-74

  Au, Jessie L S ^a,b   Kalns, John ^a   Gan, Yuebo ^a   Wientjes, M Guillaume ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; Human bladder tumors; Paclitaxel

Indexed keywords

BROXURIDINE; DNA; PACLITAXEL;

ADULT; AGED; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG EFFECT; FEMALE; HEAD AND NECK TUMOR; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE TUMOR; TRANSITIONAL CELL CARCINOMA;

ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARCINOMA, TRANSITIONAL CELL; CELL DIVISION; DNA; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; TIME FACTORS; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0031431858     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050709     Document Type: Article

References (26)

1. American Cancer Society (1996) Estimated new cancer cases and deaths by sex for all sites, United States. At http: www.cancer.org
2. Chai M, Wientjes MG, Badalament RA, Burgers JK, Au JL-S (1994) Pharmacokinetics of intravesical doxorubicin in superficial bladder cancer patients. J Urol 152: 374
3. Chen CT, Gan Y, Au JL-S, Wientjes MG (1996) Differential time dependency of antiproliferative and apoptotic effects of paclitaxel in human prostate tumors. Urol Oncol (in press)
4. Dalton JT, Wientjes MG, Badalament RA, Drago JR, Au JL-S (1991) Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res 51: 5144
5. Donaldson KL, Goolsby GL, Wahl AF (1994) Cytotoxicity of the anticancer agents cisplatin and paclitaxel during cell proliferation and the cell cycle. Int J Cancer 57: 847
6. Furukawa T, Kubota T, Hoffman RM (1995) The clinical applications of the histoculture drug response assay. Clin Cancer Res 1: 305
7. Gan Y, Wientjes MG, Badalament RA, Au JL-S (1996) Pharmacodynamics of doxorubicin in human bladder tumors. Clin Cancer Res 2: 1275
8. Gan Y, Wientjes MG, Schuller DE, Au JL-S (1996) Pharmacodynamics of taxol in human head and neck tumors. Cancer Res 56: 2086
9. Horwitz SB (1994) Taxol (paclitaxel): mechanism of action. Ann Oncol 5: 53
10. Kang H-J, Tran A, Schuller DE, Au JL-S (1996) Taxol uptake and retention in human cancer cells and solid tumors. Proc Am Assoc Cancer Res 37: 2508
11. Kerr JFR, Clay M, Harmon BV (1994) Apoptosis: its significance in cancer and cancer therapy. Cancer 73: 2013
12. Kubota T, Sasano N, Abe O, Nakao I, Kawamura E, Saito T, Endo M, Kimura K, Hiroshi D, Sasano H, Nagura H, Ogawa N, Hoffman RM and the chemosensitivity study group for the histoculture drug-response assay (1995) Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin Cancer Res 1: 1537
13. Liebmann J, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB (1994) The influence of Cremophor EL on the cell cycle effects of paclitaxel (taxol) in human tumor cell lines. Cancer Chemother Pharmacol 33: 331
14. Lopes NM, Adams EG, Pitts TW, Bhuyan BK (1993) Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32: 235
15. Richie JP (1992) Intravesical chemotherapy: treatment selection, techniques, and results. Urol Clin North Am 19: 521
16. Robbins KT, Connors KM, Storniolo AM, Hanchett C, Hoffman RM (1994) Sponge-gel-supported histoculture drug-response assay for head and neck cancer. Arch Otolaryngol Head Neck Surg 120: 288
17. Roth BJ (1995) Preliminary experience with paclitaxel in advanced bladder cancer. Semin Oncol 22: 1
18. Schmittgen TD, Wientjes MG, Badalament RA, Au JL-S (1991) Pharmacodynamics of mitomycin C in cultured human bladder tumors. Cancer Res 51: 3849
19. Schmittgen TD, Au JL-S, Wientjes MG, Badalament RA, Drago JR (1991) Cultured human bladder tumors for pharmacodynamic studies. J Urol 145: 203
20. Schmittgen TD, Weaver JM, Badalament RA, Wientjes MG, Klein EA, Young DC, Au JL-S (1994) Correlation of human bladder tumor histoculture proliferation and sensitivity to mitomycin C with tumor pathobiology. J Urol 152: 1632
21. Song D, Wientjes MG, Gan Y, Au JL-S (1997) Bladder tissue pharmacokinetics and antitumor effect of intravesical 5-fluorouridine. Clin Cancer Res (in press)
22. Song D, Wientjes MG, Au JL-S (1997) Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother Pharmacol 40: 285
23. Vesico RA, Redfern CH, Nelson RJ, Ugoretz S, Stern PH, Hoffman RM (1987) In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc Natl Acad Sci USA 84: 5029
24. Wientjes MG, Badalament RA, Au JL-S (1993) Use of pharmacologie data and computer simulations to design an efficacy trial of intravesical treatment for superficial bladder cancer. Cancer Chemother Pharmacol 32: 255
25. Wientjes MG, Badalament RA, Wang RC, Hassan F, Au JL-S (1993) Penetration of mitomycin C in human bladder. Cancer Res 53: 3314
26. Wientjes MG, Badalament RA, Au JL-S (1996) Penetration of intravesical doxorubicin in human bladders. Cancer Chemother Pharmacol 37: 539